Candela Laser gains additional approval in Japan:
This article was originally published in Clinica
Candela (US) has been granted Japanese approval to market the LaserTripter MDL-3000 for the urology market. The company already has six products approved by the Japanese Ministry of Health & Welfare which generated revenues of $7.59 million in fiscal 1994 (ended July 2nd). Japan, where Candela is leader in the urology market, is the company's largest market outside the US, says president and CEO Gerard Puorro. Corporate revenues were $29.61 million in 1994.
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.